Jump to Main Content

Meetings

Friday Satellite Symposia

FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

The 2022 FSS will be held on Friday, December 9. Each symposium will be presented once according to the program schedule and offers free registration. To register, click the “Registration” button below each title in the FSS program schedule. Check back as registration links will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each FSS session.

Please note, most, but not all sessions have a virtual component, and only some will be available on the annual meeting virtual platform. However, all sessions with a virtual component will be available (here) on the ASH website via the individual listings. Please review each listing carefully.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. The deadline for applications has passed. The 2022 FSS will take place on Friday, December 9, 2022. For more information, please review the 2022 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].


  • A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies

    This program is supported by Cleveland Clinic and AAMDSIF


    7:00 a.m. - 10:00 a.m. Central time

    VIRTUAL PROGRAM

    The Cleveland Clinic Taussig Cancer Institute and the Aplastic Anemia and MDS International Foundation join together to present a virtual and enduring continuing medical education activity focusing on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and related myeloid malignancies. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

    Chair:

    Sudipto Mukherjee, MD, PhD, MPH
    Cleveland Clinic
    Cleveland, OH

    Speakers:

    Rodrigo T. Calado, MD,PhD
    Hospital das Clínicas de Ribeirão Preto
    São Paulo, Brazil

    Gabriela S. Hobbs, MD
    Massachusetts General Hospital
    Boston, MA

    Bhumika J. Patel, MD
    Prisma Health - University Medical Group - University of South Carolina School of Medicine Greenville
    Greenville, SC

    Guillermo Sanz, MD, PhD
    Health Research Institute La Fe
    Valencia, Spain

    Craig S. Sauter, MD
    Cleveland Clinic
    Cleveland, OH

    Roland B. Walter, MD, PhD, MS
    Fred Hutchinson Cancer Center
    Seattle, WA

    Kristin Bower , Cleveland Clinic
    Email: [email protected]

    Registration for Virtual Program

    Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

    This program is supported by educational grants from Astellas, Daiichi Sankyo, Servier, and Syndax Pharmaceuticals Inc, and an independent educational grant from Gilead Sciences, Inc. Provided by NCCN in partnership with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Central time

    Hyatt Regency New Orleans
    Celestin EFGH

    This CME/CNE/CPE-certified satellite symposium on acute myeloid leukemia (AML), developed by NCCN, will feature reviews of the most recent NCCN Guidelines updates, the latest available clinical data, and practical management recommendations for different patient case scenarios. World renowned experts will provide their perspectives on recent advances in AML treatment and ongoing developments of new and novel targeted treatment options that are individualizing the care of patients with AML. Engagement with the presenting faculty will be accomplished through audience response technology that allows attendees to not only answer polling questions, but also directly text their questions, current challenges, and comments to the experts. Importantly, the faculty will highlight the latest updates to the NCCN Guidelines and provide their practical clinical insights to enhance the implementation of new evidence into practice upon return to the clinic after the ASH annual meeting. Panel discussions to include:

    • Selecting Therapy for AML Without Predictive Biomarkers/Actionable Alterations
    • Selecting Therapy for AML With Predictive Biomarkers/Actionable Alterations
    • Future Directions for Patients With AML With or Without Predictive Biomarkers/Actionable Alterations

    Chair:

    Daniel A. Pollyea, MD, MS
    University of Colorado
    Aurora, CO

    Speakers:

    Courtney D. DiNardo, MD, MSCE
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Eytan Stein, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Kristin K. Hasson , National Comprehensive Cancer Network
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies

    This program is supported by educational grants from AstraZeneca, BeiGene, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by NCCN in partnership with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Central time

    Hyatt Regency New Orleans
    Elite B

    This NCCN-developed satellite symposium presents a great opportunity for healthcare professionals to interact with experts and learn about the latest treatment advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give an overview of recent advances in CLL covering risk assessment, molecular profiling, and current and emerging therapeutics. The symposium will also feature review of the latest updates to the NCCN Guideline treatment algorithms to help guide clinical application of emerging data and consensus recommendations. Data and Guideline review will be complemented by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. New developments on the near future horizon, including the utility of measurable residual disease and ongoing clinical trials of promising investigational approaches, will also be discussed. Time for audience questions and answers during the program will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice and for attendees to obtain further clarification on the data reviewed or expert perspective on their treatment challenges.

    Chair:

    Jennifer A. Woyach, MD
    The Ohio State University
    Columbus, OH

    Speakers:

    Brian T. Hill, MD, PhD
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation
    Cleveland, OH

    Deborah M. Stephens, DO
    Huntsman Cancer Institute
    Salt Lake City, UT

    Kristin K. Hasson , National Comprehensive Cancer Network
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

    This program is supported by Sanofi


    7:00 a.m. - 10:00 a.m. Central time

    Sheraton New Orleans
    Grand Ballroom AB

    This CME activity is provided by Medical Learning Institute, Inc. and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by an educational grant from Sanofi.

    Cold agglutinin disease (primary CAD) is a rare autoimmune hemolytic anemia (AIHA) caused by a clonal B-cell lymphoproliferative disorder in which the hemolytic process is entirely complement dependent. Individuals living with this disorder experience chronic anemia and profound fatigue. Retrospective analyses have also demonstrated other potential complications for patients with CAD, including an increased risk of thromboembolic events and early mortality.

    In this live educational symposium, a panel of expert faculty will discuss an appropriate diagnostic workup in any patient with AIHA to help confirm or rule out the possibility of CAD and review the rationale for inhibition of complement C1s as an effective long-term therapy for CAD. This activity will also discuss how to implement classical complement pathway-targeted therapies into treatment plans for CAD consistent with patient-specific characteristics and other prescribing considerations.

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management

    This program is supported by AstraZeneca and Lilly


    7:00 a.m. - 10:00 a.m. Central time

    Hyatt Regency New Orleans
    Empire CD

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by independent educational grants from AstraZeneca and Lilly.

    Across B-cell non-Hodgkin lymphoma (NHL) settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell) features.

    PeerView’s latest “Clinical Consults” event will explore the implications of these new developments by pairing real-world case discussions with mini lecture segments focusing on the present and future of targeted agent classes in aggressive lymphoma settings. Throughout, the experts will highlight evidence supporting novel BTK-based combinations, BTK inhibitor regimens in diverse DLBCL patient populations, and the important safety considerations necessary for successful use of targeted agents in MCL and DLBCL. Register today to learn how to effectively target treatment for your patients with aggressive lymphoma!

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    Maintaining ‘Intensity’ for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

    This program is supported by Jazz Pharmaceuticals


    7:00 a.m. - 10:00 a.m. Central time

    Sheraton New Orleans
    Napoleon B

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

    Using PeerView’s ‘Clinical Consults’ format, this unique event will provide learners with guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes—and demonstrate how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. Using serial case vignettes inspired by real-world scenarios, the panelists will debate the selection and use of novel cytotoxic platforms, FLT3, and BCL-2 inhibitors, and novel emerging approaches in a range of difficult-to-treat patient populations. Case-based conversations will link directly with ‘mini-lecture’ segments covering upfront prognostic assessment, identification of candidates for intensive upfront therapy, managing important subtypes such as secondary AML/AML-MRC and FLT3-mutated disease, and the shifting goals of modern therapy, including the potential to offer HCT to a growing proportion of patients with challenging disease presentations.

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    Myelodysplastic Syndromes 2022: Today and Tomorrow

    This program is supported by MDS Foundation, Inc.


    7:00 a.m. - 10:00 a.m. Central time

    Ernest N. Morial Convention Center
    La Nouvelle Orleans Ballroom AB

    For In-Person Participants Only

    The 2022 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines evidence on current practice with information that might be applied in the future.

    Chairs:

    Moshe Mittelman, MD
    Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel

    Valeria Santini, MD
    AOU Careggi-University of Florence
    Florence, Italy

    Speakers:

    Rafael Bejar, MD, PhD
    University of California San Diego Moores Cancer Center
    La Jolla, CA

    Rena Buckstein
    Odette Cancer Centre
    Toronto, ON, Canada

    Jane Churpek, MD
    University of Wisconsin School of Medicine and Public Health
    Madison, WI

    Theo M de Witte, MD
    Radboud University Medical Centre
    Nijmegen, Netherlands

    Peter C. Grayson, MD, Msc
    National Institute of Arthritis, Musculoskeletal, and Skin Diseases. National Institutes of Health
    Bethesda, MD

    Elizabeth A. Griffiths, MD
    Roswell Park Comprehensive Cancer Center
    Buffalo, NY

    Yasushi Miyazaki, MD
    Atomic Bomb Disease Institute, Nagasaki University
    Nagasaki, Japan

    Sophie Park, MD, PhD
    Centre Hospitalo-Universitaire Grenoble Alpes
    Grenoble, France

    Lewis R. Silverman, MD
    Icahn School of Medicine at Mount Sinai
    New York City, NY

    Lea Harrison , MDS Foundation, Inc.
    Email: [email protected]

    Registration for In-Person Program

    Navigating the Frontier of Hematologic Malignancy Therapies

    This program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.


    7:00 a.m. - 10:00 a.m. Central time

    Ernest N. Morial Convention Center
    Great Hall AD

    For In-Person Participants Only

    The Friday Satellite Symposium, "Navigating the Frontier of Hematologic Malignancy Therapies," will directly address the most relevant information available at the time of the presentation with regard to:

    • Bispecific Antibodies: Promising Therapeutics for Multiple Myeloma
    • New Strategies for T Cell Immunotherapy: "Off-the-Shelf" T Cell Therapies in the Era of CAR-T
    • Targeting Intracellular Proteins: PROTACs in the Management of Hematologic Cancers
    • Antibody-Drug Conjugates: Overcoming Limitations in the Management of AML
    • Risk Prediction and Individualized Therapy: Role of ctDNA in DLBCL

    Chair:

    Helen E. Heslop, MD, DSc (Hon)
    Baylor College of Medicine
    Houston, TX

    Speakers:

    Katherine Donovan, PhD
    Dana Farber Cancer Institute
    Boston, MA

    Soheil Meshinchi, M.D., Ph.D.
    Fred Hutchinson Cancer Center
    Seattle, WA

    Mark Roschewski, MD
    National Cancer Institute
    Bethesda, MD

    Saad Usmani, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Cherie Haley , RMEI Medical Education, LLC
    Email: [email protected]

    Registration for In-Person Program

    Putting the CAR(T) Before the Horse: Practicalities of T Cell–Activating Therapies in Multiple Myeloma

    This program is supported by The Multiple Myeloma Research Foundation with funding provided by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Legend Biotech USA Inc.


    7:00 a.m. - 10:00 a.m. Central time

    VIRTUAL PROGRAM

    To help hematologist-oncologists overcome the challenges of using T cell–activating therapy, the proposed virtual FSS will feature presentations highlighting the challenges faced by community practices using T cell–activating therapies and case studies that present strategies for optimal use of these therapies.

    The symposium will feature discussion of key clinical data on the use of T cell activating therapies with an emphasis on practicalities of their use in the community practice setting. Each speaker will highlight the unique challenges faced by community practices through the use of case studies where the audience will be polled on how their practices currently use and then intend to use these therapies in the future.

    The virtual program will allow learners to participate in audience polling, complete pre- and post-activity surveys and the program evaluation and submit questions to be answered by the speakers.

    Chairs:

    Hearn J. Cho, MD, PhD
    Multiple Myeloma Research Foundation
    Norwalk, CT

    Paul G. Richardson, MD
    Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
    Boston, MA

    A. Keith Stewart, MBChB
    University of Toronto, Princess Margaret Cancer Centre, University Health Network
    Toronto, ON, Canada

    Speakers:

    Amrita Y. Krishnan, MD, FACP
    Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center
    Duarte, CA

    Suzanne Lentzsch, MD, PhD
    Columbia University Medical Center
    New York, NY

    Karen Tenaglia , RedMedEd
    Email: [email protected]

    Registration for Virtual Program

    Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms into Patient Care

    This program is supported by Incyte Corporation and MorphoSys US Inc.


    7:00 a.m. - 10:00 a.m. Central time

    Sheraton New Orleans
    Rhythms Ballroom

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by educational grants from Incyte Corporation and MorphoSys US Inc.

    The era of conventional chemoimmunotherapy as a universal treatment approach to DLBCL is being transformed by the emergence of potent, antibody-based platforms. These include novel CD19-directed antibodies and antibody-drug conjugates, which have afforded clinicians a wider variety of effective therapeutic options that may be tailored to specific disease- and patient-related features, as well as CD3 x CD20 bispecific antibodies in DLBCL, which may soon play a role in pretreated DLBCL settings.

    PeerView’s unique Seminars & Tumor Board educational design will explore these developments by pairing case scenarios with the practice-changing evidence that continues to support the rapid integration of novel antibody platforms into the personalized management of DLBCL. Each panel-based Tumor Board discussion will address challenges such as: the identification of candidates for treatment with novel antibodies; therapeutic sequencing and bridging strategies; and appropriate safety management and monitoring. Join the experts to hear about these innovations in New Orleans for the 2022 annual hematology meeting!

    Chair:

    Grzegorz (Greg) Nowakowski, MD
    Mayo Clinic
    Rochester, MN

    Speakers:

    Paolo F. Caimi, MD
    Cleveland Clinic Lerner College of Medicine, Case Comprehensive Cancer Center
    Cleveland, OH

    Stephen J. Schuster, MD
    Hospital of the University of Pennsylvania
    Philadelphia, PA

    Margaret Walker , Peerview Institute For Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

    This program is supported by Bristol Myers Squibb and Kite, a Gilead Company


    7:00 a.m. - 10:00 a.m. Central time

    Hyatt Regency New Orleans
    Empire B

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported through educational grants from Bristol Myers Squibb and Kite, a Gilead Company.

    Are you up to date with the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into a widening circle of non-Hodgkin lymphoma (NHL) treatment settings? Recent advances, driven by the use of CD19-directed cell therapy constructs, are proving that CAR-T options have wider applications in diseases such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The current clinical challenge is how to best reflect the reality of cellular therapy—including the availability of new constructs, recent regulatory approvals, and real-world experience.

    This PeerView symposium will deliver guidance on the further integration of CAR-T therapy into lymphoma management. Using a ‘Seminars and Tumor Board’ format, the panelists will draw on real-world cases and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including management of unique toxicities to coordination with specialized care.

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

    This program is supported by AbbVie, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.


    7:00 a.m. - 10:00 a.m. Central time

    Sheraton New Orleans
    Grand Ballroom C

    This CME/MOC activity is provided by Medical Learning Institute, Inc. and developed with our educational partners, PVI, PeerView Institute for Medical Education and HealthTree Foundation.

    This activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

    There remains a need for additional therapeutic efforts to improve outcomes in RRMM while delivering safe care and attempting to eradicate disease. The emergence of BCMA as a target in MM treatment has led to several innovative strategies with demonstrated ability to evade resistance to prior therapies and induce deep and durable responses. Modern care in RRMM should therefore focus on integrating BCMA-targeting options, including ADCs, bispecific and trispecific agents, and CAR-T therapy.

    This MasterClass and Case Forum event will offer learners guidance on the “road to remission” in MM and recent advances with BCMA therapies in challenging treatment settings. Experts will discuss therapy selection with BCMA antibodies and CAR-T therapy, and the optimization of care in pretreated disease. Each segment will also feature patient insights to further illustrate the impact of BCMA-targeting options throughout the MM therapeutic journey. Get on the “road to remission” and don’t miss this important event!

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    The Sequel to the Targeted Therapy Era in CML: Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans

    This program is supported by Novartis Pharmaceuticals Corporation


    7:00 a.m. - 10:00 a.m. Central time

    Sheraton New Orleans
    Napoleon C

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

    The validation of TKIs as a treatment for patients with CML began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. While the earlier generation of TKIs led to greatly improved prognoses and more personalized care (informed by response monitoring and mutational analysis techniques), continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of effective options across CML treatment settings and patient populations.

    In a new event from PeerView, an expert panel will provide foundational evidence supporting new targeted therapy management models in a variety of settings. These lectures will inform subsequent case-based debates on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts will highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Join us to help write the sequel on optimal management of patients with CML!

    Chair:

    Vivian Oehler, MD
    Fred Hutchinson Cancer Center
    Seattle, WA

    Speakers:

    Michael Mauro, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Kendra Sweet, MD
    Moffitt Cancer Center
    Tampa, FL

    Margaret Walker , Peerview Institute For Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    The Winning Way with BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

    This program is supported by AstraZeneca


    7:00 a.m. - 10:00 a.m. Central time

    Hyatt Regency New Orleans
    Empire A

    This CME/MOC activity is provided by Medical Learning Institute, Inc. and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by an independent educational grant from AstraZeneca.

    The emergence and validation of the BTK inhibitor agent class in CLL has proven to be the foundation of modern patient management, allowing for the personalized selection of therapy for individuals presenting with different prognostic features or comorbid illnesses. Currently available BTK for CLL are effective as monotherapy, useful in combination with other agents (such as CD20 antibodies), and active in many different settings. Choosing effective, personalized therapy with BTKi options will likely be a clinical question for the foreseeable future.

    This PeerView Clinical Consults event will provide evidence-based guidance for using BTK therapy in CLL based on longer follow-up data from phase 3 trials and head-to-head evidence, and will demonstrate how the latest safety and efficacy findings can inform treatment selection. Throughout, the expert panelists will share and comment on real-world cases that reflect modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and efficacy. Don’t miss this opportunity to learn about customizing BTKi therapy from our experts!

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

  • A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

    This program is supported by educational grants from Amgen, Janssen Biotech, Inc., Karyopharm Therapeutics Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc. Provided by CCO in partnership with IMF


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Elite B

    Attendees of the annual International Myeloma Foundation/Clinical Care Options symposium are invited to interact with a panel of international experts as they discuss the evolving treatment landscape for multiple myeloma (MM) and how they are integrating management approaches in their own clinical practice.

    An international panel of experts will discuss current clinical questions using available evidence, provide their answers to challenges affecting therapeutic decisions, and highlight emerging treatment options for MM. They share their treatment recommendations for a series of patient cases while attendees vote on these cases and compare their answers with experts. Attendees can text questions directly to the panel for discussion throughout the symposium.

    Topics for discussion:

    • How to determine risk of progression for smoldering MM
    • When to treat patients with smoldering MM
    • Optimal induction therapy for “average” patients with newly diagnosed MM; patient/disease factors changing treatment approaches
    • Ideal duration of therapy for first-line MM
    • Selecting therapy at first relapse
    • Individualizing therapy for an “average” patient after multiple relapses; patient/disease factors changing treatment approaches
    • Therapy considerations after BCMA-targeted treatment

    Review of 2023 myeloma treatment algorithm

    Chair:

    Brian G.M. Durie, MD
    Cedars-Sinai Outpatient Cancer Center
    Los Angeles, CA

    Speakers:

    Shaji K Kumar, MD
    Mayo Clinic
    Rochester, MN

    Thomas Martin, MD
    University of California, San Francisco
    San Francisco, CA

    Philippe Moreau, MD
    Hematology Department, University Hospital Hôtel-Dieu
    Nantes, France

    S. Vincent Rajkumar, MD
    Mayo Clinic
    Rochester, MN

    Jesús San-Miguel, MD, PhD
    Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA
    Pamplona, Spain

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults

    This program is supported by educational grant from Jazz Pharmaceuticals. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Napoleon C

    Dose-intensified, multiagent chemotherapy regimens, in which asparaginase plays a prominent role, have substantially improved outcomes for children and adolescents/young adults (AYAs) with acute lymphoblastic leukemia (ALL) in recent decades and are playing an increasing role in adult and older adult patients. This symposium, focused on the latest evidence to optimize the care of older patients with ALL using asparaginase, will provide practical expert guidance on current therapeutic strategies for monitoring/identifying clinical and subclinical asparaginase hypersensitivity and the latest recommendations for patient management. The symposium agenda will include didactic data presentations by experts with case challenges, moderated panel discussion, and audience interactivity with time for Q&A. Along with the experts, audience participants will explore key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as receive personal expert treatment recommendations for each case. Throughout the symposium, learners will vote on case scenarios and text questions directly to the expert panel for their consideration. Discussion topics will include:

    • Overview of treatment algorithms for ALL and importance of asparaginase
    • Strategies to increase completion of asparaginase-based treatment and managing hypersensitivity
    • Leveraging the lessons and experience treating pediatric patients to optimize the care of AYA and adult patients with ALL

    Chair:

    Daniel J. DeAngelo, MD, PhD
    Harvard Medical School, Dana-Farber Cancer Institute
    Boston, MA

    Speakers:

    Emily K Curran, MD
    University of Cincinnati Cancer Center
    Cincinnati, OH

    Kjeld Schmiegelow, MD, DMSc
    Rigshospitalet, University of Copenhagen
    Copenhagen, Denmark

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Celestin ABCD

    This CME-accredited program will focus on the management of patients with chronic lymphocytic leukemia. Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 4 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The Working Group will be video-recorded and RTP will select excerpts for presentation during the live meeting. The agenda for the symposium will be divided into 5 modules, each featuring the presentation and discussion of select video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, clinician attendees will use iPads to participate in a premeeting survey related to the topics, questions and cases that will be discussed. Polling results will be interspersed throughout each module to foster additional debate.

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion

    This program is supported by educational grants from Daiichi Sankyo, Inc., Kyowa Kirin, Inc., and Seagen. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Rhythms Ballroom

    This interactive symposium will feature presentations and panel discussion on the management of T-cell lymphomas with perspectives and recommendations from multiple experts. Faculty presenters will review cutting-edge clinical evidence, real-world data, and share their experience. Then, along with the audience, the panel will work through multiple challenging cases highlighting evolving aspects of T-cell lymphoma care. Finally, the expert panel will provide their insights on a consensus treatment algorithm for T-cell lymphomas in 2023. Discussion, presentation, and case challenge topics will include: modern molecular and phenotypic workup for T-cell lymphomas; first-line and subsequent therapy according to PTCL subtypes; first-line and subsequent therapy for CTCL; management of treatment-related adverse events; key clinical trials for patients with T-cell lymphomas.

    Chair:

    Steven M. Horwitz, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Speakers:

    Pamela B. Allen, MD
    Emory University School of Medicine
    Decatur, GA

    Kerry J. Savage, MD, MSc, FRCPC
    University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer
    Vancouver, BC, Canada

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias

    This program is supported by Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Rigel Pharmaceuticals


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    243-245

    Rare hemolytic anemias pose significant challenges to the hematology/oncology community. The diagnostic workup is complex and multifaceted, including multiple different diagnostic procedures, as diagnoses are often diagnoses of exclusion. Accurate diagnoses require a deep understanding of multiple hematological diseases—including rare diseases, such as hemolytic anemias—clinicians may marginally encounter. Moreover, once an accurate diagnosis is established, treatment decision-making may be suboptimal, as keeping abreast of practice-changing data on current and emerging treatments can be challenging for health care providers. The educational gaps regarding awareness of these rare disorders, their diagnostic criteria, methods for differential diagnosis, and current/emerging treatment options have been further deepened by the COVID-19 pandemic and physicians’ inability to travel and attend major scientific meetings in 2020 and 2021. The present format will give hematologists the opportunity to review the latest guidelines on diagnoses for the aforementioned hemolytic anemias and reflect on potential real-world clinical scenarios through case-based discussion, and discuss how they might integrate relevant evidence into treatment paradigms; this format represents a vehicle that enhances learning about these rare diseases and key emerging treatment concepts.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

    This program is supported by educational grants from Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics Inc., and Novartis Pharmaceuticals Corporation. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Napoleon B

    New innovations have changed clinical practice in the management of myelodysplastic syndromes (MDS) and this interactive symposium will focus on evolving therapeutic standards and emerging therapeutic options with expert faculty providing practical insights for disease and supportive care management of MDS across the spectrum of low- to high-risk disease and following HMA failure. Using different case presentations, the experts will discuss key clinical questions, available supporting evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the symposium, the audience will be able to vote on case scenarios and directly text questions regarding their specific challenges to the panel for their consideration. Discussion topics will include:

    • Risk stratification in MDS
    • Managing anemia in very low–risk, low-risk, or intermediate-risk MDS
    • Novel therapeutic approaches for the treatment of lower-risk MDS
    • Latest guidance on the treatment of higher-risk MDS and managing relapsed/refractory MDS

    Chair:

    Rami S. Komrokji
    H. Lee Moffitt Cancer Center and Research Institute
    Tampa, FL

    Speakers:

    María Diez-Campelo, MD, PhD
    University Hospital of Salamanca
    Salamanca, Spain

    Amer M. Zeidan, MD
    Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center
    New Haven, CT

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow

    This program is supported by Genmab, Kite Pharma, Inc., Kyowa Kirin


    11:00 a.m. - 2:00 p.m. Central time

    VIRTUAL PROGRAM

    The treatment of B-cell lymphomas continues to evolve with the introduction of new targeted agents, immunotherapies, and combination strategies, providing much-needed new options and increasing the complexity of therapeutic decision-making. Ongoing clinical trials have demonstrated the activity and safety of novel approaches, which may soon provide additional options.

    During this live virtual symposium, the expert faculty panel will present recent updates in the treatment of indolent and aggressive B-cell lymphomas and discuss the impact of these advances on clinical practice. Practical strategies for adverse event monitoring, mitigation, and management will also be discussed.

    Chair:

    Andre H. Goy, MD, MS
    Hackensack Meridian School of Medicine
    Hackensack, NJ

    Speakers:

    Lorenzo Falchi, MD
    Istitutto Superiore Di Sanita'
    Rome, Italy

    Lori Leslie, MD
    Hackensack Meridian School of Medicine
    Hackensack, NJ

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for Virtual Program

    Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA

    This program is supported by Alexion Pharmaceuticals, Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire B

    This 90-minute, live, interactive symposium will feature discussions which revolve around the implications of complement in specific hematologic disorders. Segment 1 will review the new horizons regarding complement inhibition and hematopoietic stem cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Segment 2 will feature key considerations for navigating the patient journey for paroxysmal nocturnal hemoglobinuria (PNH). Segment 3 will highlight best practices for managing patients with atypical hemolytic uremic syndrome (aHUS) in the community, and Segment 4 will underscore the value of the patient voice. A Q&A session at the end will allow for expert faculty to answer remaining questions from the audience.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Elevating Equity in Caring For Patients With Hematologic Malignancies

    This program is supported by AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Legend Biotech, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc., Regeneron Pharmaceuticals, Gilead Sciences, Inc., and Lilly


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Celestin EFGH

    This 90-minute live symposium, developed through a collaboration between Medscape Oncology and The Leukemia & Lymphoma Society is designed to increase awareness of health disparities for clinicians treating patients with hematologic malignancies from diverse backgrounds and provide strategies for overcoming barriers to equitable care. A multidisciplinary panel consisting of a hematologist/oncologist, nurse practitioner and patient advocate will provide a comprehensive review of specific issues that affect patients with hematologic malignancies, including guidance for community practice, clinical strategies to address disparities, healthcare policies, and patient access considerations.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Expert Illustrations and Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease

    This program is supported by GlaxoSmithKline


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    217-219

    A common complication of chronic kidney disease (CKD), anemia is associated with impaired cognition, lower quality of life, and increased cardiac risk, medical expense, and mortality. Several new agents that stimulate erythropoiesis are in late-stage development for the management of CKD-related anemia. In particular, the hypoxia-inducing factor (HIF) pathway has become an attractive target for modulating iron metabolism. This interactive program will review guideline recommendations for anemia assessment and management and examine the latest data on new and emerging agents.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/ Refractory Disease?

    This program is supported by Regeneron Pharmaceuticals, Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    Great Hall BC

    Do not miss the first ever Multiple Myeloma Clinical OlympicsSM symposium preceding the ASH 2022! All prospective “Olympians” will join 1 of 3 country teams to compete in a series of clinical events by answering challenge questions (via provided iPads) related to the use of BCMA-targeted therapies in relapsed/refractory multiple myeloma. Individual learners earn points for their team by responding correctly to challenges in each event, after which the big screens will display the Gold, Silver, and Bronze medal winners. In the closing ceremonies of the Clinical OlympicsSM, the all-around winners from all 3 events will be announced, as well as the leaderboard for the top 15 individual performers. Join us for the expert-driven scientific exchange, but also for some friendly competition and fun!

    Chair:

    Sundar Jagannath
    Mount Sinai Medical Center
    New York, NY

    Speakers:

    James E. Hoffman, MD
    Sylvester Comprehensive Cancer Center, University of Miami
    Miami, FL

    Maria-Victoria Mateos, MD
    University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC)
    Salamanca, Spain

    Steph Kielt , RMEI Medical Education, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

    This program is supported by AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Lilly, Merck & Co., Inc., and Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire A

    This event will feature insights on the patient journey from Terry Evans, a 22-year CLL survivor and patient advocate.

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and the CLL Society.

    This activity is supported by independent educational grants from AbbVie; AstraZeneca; BeiGene; Bristol Myers Squibb; Lilly; Merck & Co., Inc.; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

    The current CLL management tool kit is expanding to include covalent and noncovalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies. This has allowed for the “fine-tuning” of patient care based on different prognostic features or comorbid illnesses, potentially allowing clinicians to overcome challenges around planning treatment over several lines of therapy while achieving deep, durable responses in TN and R/R CLL.

    PeerView’s unique “Seminars & Tumor Board” live event will explore how this wave of innovation is changing practice by offering expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care across the spectrum of CLL. Throughout, the panelists will review the personalized, evidence-based selection of upfront treatment strategies; therapeutic sequencing in progressive disease settings; and best practices for safety management. Join us for this exciting case-based event!

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

    How We Do It™: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow

    This program is supported by Constellation Pharmaceuticals, A MorphoSys Company, Incyte Corporation, Protagonist Therapeutics, SDP Oncology, and PharmaEssentia USA


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom DE

    Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and myelofibrosis (MF) are potentially life-threatening hematologic malignancies that require careful consideration of patient and disease characteristics for management. However, advances in risk stratification, supportive care, and treatment options have led to substantial improvements in symptom control and quality of life. As new therapies continue to emerge for management of PV and MF, clinicians face increasingly complex decision-making for optimal treatment of individual patients.

    This live activity is designed to provide clinicians with an opportunity to interact with experts in the management of PV and MF as they give critical updates from transformative studies presented at recent hematology conferences. Faculty will provide their perspectives on recently presented data in the context of patient case scenarios, while featuring a forum to discuss how these findings are likely to shift the treatment landscape in 2023.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult

    This program is supported by Amgen, Inc., Jazz Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    La Nouvelle Orleans Ballroom C

    Acute lymphoblastic leukemia (ALL) is the most common form of childhood leukemia and accounts for approximately 20% of adult leukemias. Advances in the treatment of ALL have largely resulted from a better genetic understanding of the disease. Therefore, careful risk stratification is an essential prerequisite for ALL treatment planning and requires clinicians to be knowledgeable of cytogenetic and immunophenotype characteristics. This will improve knowledge of current and emerging agents in management of patients.

    The Medical Crossfire® satellite symposium will be presented at the 2022 ASH Annual Meeting held in New Orleans, Louisiana, and will provide a format for expert hematology oncologists to discuss the latest therapies and how to best integrate them into ALL treatment paradigms. The case-based agenda will allow in-depth review of patient scenarios integrated with relevant evidence into real-world practice and will span the spectrum of disease. Discussion topics will include individualized treatment planning based on disease characteristics, MRD-driven decision-making, antibody-based therapies and CAR T strategies, as well as barriers to optimized integration of these novel agents, and best practices for the management of adverse events.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

    This program is supported by AbbVie, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    343-345

    The emergence of new therapeutic mechanisms of action has led to significant benefits in terms of response and survival for patients with hematologic malignancies. Despite these advances, patients will still experience relapse due to the presence of measurable (or minimal) residual disease (MRD) after therapy. The incorporation of MRD status in the treatment algorithm also triggers other important decisions, such as selecting an assay, determining sensitivity levels, and assessing the impact of other factors, such as high-risk disease characteristics. It is important for clinicians to effectively evaluate and manage MRD to maximize the benefits of antineoplastic therapy.

    This cutting-edge program will provide physicians with the tools to apply MRD assessment with confidence in their clinical practice. The expert faculty will address the key considerations of MRD testing in a wide range of hematologic malignancies, including acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). Interactive Medical Crossfire® panels will allow discussion on the application of data to clinical practice, and participants will also be able to ask the experts questions directly.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Navigating a Changing Landscape Together: Gene Therapy for Hemophilia

    This program is supported by BioMarin Pharmaceutical Inc., CSL Behring, and Spark Therapeutics, Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    393-396

    Although patient and clinician goals for gene therapy for hemophilia may be similar, their experiences are vastly different. This Friday Satellite Symposium focuses on strategies to engage the multidisciplinary care team and patients through a shared decision-making process regarding gene therapy for hemophilia. Dr. Michael Recht and Dr. Guy Young will lead the audience through recent clinical trial updates and how to effectively communicate the latest data to patients.

    You will also hear from Luke Pembroke, a patient who has undergone gene therapy for hemophilia, about his experience, questions, and best practices. Jennifer Maahs, NP, will guide you through a case study that provides tools to share with your team and patients. Through role-playing and real patient experiences, this engaging symposium will impact your ability to support patients and families as they consider clinical trials or gene therapy as a future therapeutic option.

    Amanda Noe, The France Foundation
    Email: [email protected]

    Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma—Integrating New Treatments

    This program is supported by independent educational grants from ADC Therapeutics America, Inc.; Genmab; and Kite, a Gilead Company, Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom C

    This is a 90-minute, case-based live symposium on diffuse large B-cell lymphoma (DLBCL). Join us as a panel of 3 hematologists/oncologists with expertise in relapsed/refractory (R/R) DLBCL discuss treatment, side effect management, and emerging therapies. The program will begin with a brief review of the challenges in treating DLBCL, setting the stage for a discussion of available therapies and the ongoing development of novel treatment options for patients with R/R DLBCL who are not candidates for hematopoietic stem cell transplantation (HSCT) or whose disease progresses after HSCT. This will be followed by expert-led, real-life case-based examples to highlight the role of available therapies and ways to optimize the use of novel treatment options for these patients with R/R DLBCL. The program will conclude with a review of currently available trials, a discussion of the likely therapeutic landscape of the future, and a lively and engaging Q&A session with the panelists.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

    This program is supported by Bristol Myers Squibb, Janssen Biotech, Inc., GlaxoSmithKline, Karyopharm Therapeutics, and Sanofi.


    11:00 a.m. - 2:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire CD

    This 90-minute live symposium will address the practical aspects and clinical implications of incorporating triplet and quadruplet therapies in the care of patients with multiple myeloma (MM). The program will consist of 1 moderator and 2 panelists, all with expertise as hematologist/oncologists in the field of MM. Discussion will include the latest clinical data for multidrug therapies, patient selection, and management of adverse effects. Case challenges, real-time audience polling questions, and Q&A with the expert faculty will keep the program highly interactive and ensure an organic educational experience.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections

    This program is supported by Merck & Co., Inc. and Takeda Pharmaceuticals, U.S.A., Inc.


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    La Nouvelle Orleans Ballroom AB

    Cytomegalovirus (CMV) infection is a common complication of immunosuppression and has been identified as one of the most important complications in patients who undergo hematopoietic stem cell transplants (HSCT). Current management strategies for prevention of CMV infections in transplant patients who are seropositive or have seropositive donors include antiviral prophylaxis and preemptive therapy; however, these drugs have been associated with significant adverse events. Recent approvals of new treatments for CMV and active research continues across a span of categories, including novel therapeutics, new indications for previously approved therapies, better monitoring strategies, and new strategies for treating resistant/refractory CMV infections.

    This 2-hour live, hybrid satellite symposium will highlight current and emerging therapeutic options for patients who experience CMV infections post-HSCT. In this educational program, expert faculty will discuss risk factors for CMV and its impact on patient outcomes, assess best practices to monitor patients for CMV, and engage in spirited debates on primary and secondary prevention strategies as well as management of CMV infections in transplant recipients.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT

    This program is supported by CSL Behring LLC.


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    Great Hall AD

    Do not miss the first ever graft-versus-host disease (GVHD) Clinical OlympicsSM symposium preceding the ASH 2022! All prospective “Olympians” will join 1 of 3 country teams to compete in a series of clinical events by answering challenge questions (via provided iPads) on the management of GVHD in patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT). Individual learners earn points for their team by responding correctly to challenges in each event, after which the big screens will display the Gold, Silver, and Bronze medal winners. In the closing ceremonies of the Clinical OlympicsSM, the all-around winners from all 3 events will be announced, as well as the leaderboard for the top 15 individual performers. Join us for the expert-driven scientific exchange, but also for some friendly competition and fun!

    Chair:

    Miguel-Angel Perales, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Speakers:

    Nelson J. Chao, MD, MBA
    Duke University Medical Center
    Durham, NC

    Sung W. Choi, MD, MS
    Children’s Hospital of Michigan
    Ann Arbor, MI

    Elizabeth Gray , RMEI Medical Education, LLC
    Email: [email protected]

    Registration for In-Person Program

    Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan

    This program is supported by Agios Pharmaceuticals, Inc., Chiesi USA, Vertex Pharmaceuticals, and Forma Therapeutics


    11:00 a.m. - 2:00 p.m. Central time

    Ernest N. Morial Convention Center
    208-210

    Significant progress has been made in the field of sickle cell disease (SCD) in recent years, leading to increased life expectancy for patients. However, patients with SCD can develop comorbid conditions—adding to the complexity of their treatment—and health care providers may lack the tools to provide optimal pain management and treat complications in adult patients and teens moving out of the pediatric setting.

    This educational activity will focus on key components of appropriate pain management, the challenges of complications and comorbid conditions, the changing needs of patients across the lifespan, and the importance of individualized and well-coordinated treatment strategies for individuals with SCD.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis

    This program is supported by CTI BioPharma Corp.


    11:00 a.m. - 2:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom AB

    This engaging 90-minute live and virtual hybrid educational symposium will be held proceeding the ASH annual meeting. The program is organized in a lively Day Time Talk Show style, with experts in the field of myelofibrosis (MF) serving as both "Host" and "Faculty Guests" who will take turns reviewing a Top Ten Things to Know About Cytopenic MF list. During review, they will highlight key discussion points and questions while emphasizing the role of Janus kinase (JAK) inhibitors in the treatment paradigm. The agenda will incorporate audience voting/surveys and discussion throughout. It will also include live Q&Q and panel discussion to maximize scientific exchange and sharing of expert perspectives.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

  • A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B

    This program is supported by CSL Behring LLC


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    217-219

    In hemophilia B, an absence of clotting factor IX leads to a failure to facilitate and stabilize the primary platelet and fibrin plug that initially forms a clot. As a result, patients will experience prolonged bleeding. Despite recent improvements in treatment options, however, hemophilia B continues to have a significant negative impact on patients’ health-related quality of life. Gene therapy for hemophilia B has the potential to reduce the treatment burden for patients and their care providers by eliminating the need for regular prophylaxis.

    This program will feature didactic presentations coupled with a series of panel discussions and audience Q&A sessions, as well as videos to depict pathophysiology and patient counseling case scenarios. This combination of teaching formats will provide an engaging and practical learning environment for medical professionals who care for patients with hemophilia B.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis

    This program is supported by educational grants from AbbVie and CTI Biopharma. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Central time

    Sheraton New Orleans
    Rhythms Ballroom

    During this symposium learn from experts their perspective on evolving concepts and practical insights into the diagnosis, risk stratification, and management of myelofibrosis (MF). Each topic of the symposium will include a case review, didactic presentation, and interactive panel and audience engagement. Symposium participants can expect to gain answers to key clinical questions, insights on available evidence and challenges that impact therapeutic decisions, as well as the expert treatment recommendations for each case. Throughout the symposium, participants will be able to vote on case scenarios and text their questions, current challenges, and cases to the panel for their consideration. Discussion topics include:

    • Risk stratification and prognosis of MF
    • Management of newly diagnosed MF
    • Recognizing patterns of first-line treatment failure
    • Second-line treatment options for MF
    • Managing disease- and treatment-related symptoms

    Chair:

    Srdan Verstovsek, MD, PhD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Speakers:

    Brady L. Stein, MD, MHS
    Northwestern University
    Chicago, IL

    Abdulraheem Yacoub, MD
    The University of Kansas Cancer Center
    Leawood, KS

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma - What Clinicians Want to Know (Part 2 of a 3-part CME-accredited Symposia Series)

    This program is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, a Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Celestin ABCD

    This CME-accredited program will focus on the management of patients with Hodgkin and Non-Hodgkin Lymphoma. Five investigators will serve a faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 4 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The Working Group will be video-recorded and RTP will select excerpts for presentation during the live meeting. The agenda for the symposium will be divided into 5 modules, each featuring presentation and discussion of select video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, clinician attendees will use iPads to participate in a premeeting survey related to the topics, questions and cases that will be discussed. Polling results will be interspersed throughout each module to foster additional debate.

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies

    This program is supported by educational grants from Bristol Myers Squibb, Genmab US, Inc. and AbbVie, Karyopharm Therapeutics Inc., and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Central time

    Sheraton New Orleans
    Napoleon B

    Attendees of this aggressive B-cell lymphoma symposium are invited to engage and interact with a panel of experts as they discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) and how they are integrating state-of-the-art management approaches in their own clinical practice. The expert panel will discuss current clinical questions using available evidence, provide their answers to challenges affecting therapeutic decisions, and highlight emerging treatment options from new classes of agents in DLBCL and MCL. Presenters will review challenging patient cases while attendees vote on these cases and compare their answers with experts. Attendees can text questions directly to the panel for discussion throughout the symposium. Topics for discussion:

    • Timeline of approvals and discoveries for DLBCL and MCL
    • Patient selection and sequencing of new and emerging agents within the patient care continuum
    • Differentiating between novel and currently approved classes of agents and among agents within each class
    • Integrating precision medicine approaches into the current algorithm for induction, consolidation, and maintenance therapy
    • Key considerations for clinical application of new data and agents into practice or clinical trial enrollment
    • 2023 treatment algorithms for DLBCL and MCL

    Chair:

    John P. Leonard, MD
    Weill Cornell Medicine and New York Presbyterian Hospital
    New York, NY

    Speakers:

    John N. Allan
    Weill Cornell Medicine/New York Presbyterian Hospital
    New York, NY

    Laurie H. Sehn, MD, MPH
    BC Cancer Centre for Lymphoid Cancer and The University of British Columbia
    Vancouver, BC, Canada

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

    This program is supported by educational grants from Alexion Pharmaceuticals and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Elite B

    This interactive symposium will feature presentations and case-based panel discussions with perspectives and treatment recommendations from multiple experts. In addition, the expert panel will address audience questions, challenges, and cases identified in the “Live Case and Question Submission” that are sent directly to the faculty. This symposium format will include review of cutting-edge clinical evidence and expert perspectives on evolving treatment algorithms for AL amyloidosis in 2023. Discussion and presentation topics include: Biology, clinical presentation, and diagnostic approach for AL amyloidosis; Current/evolving management algorithm for the patient with newly diagnosed AL amyloidosis and the management of AL amyloidosis at relapse; Common challenges and pitfalls in the management of patients with AL amyloidosis; Future Directions in amyloidosis treatment.

    Chair:

    Angela Dispenzieri, MD
    Mayo Clinic
    Rochester, MN

    Speakers:

    Anita D'Souza, MD,MS
    The Medical College of Wisconsin Inc.
    Milwaukee, WI

    Jeffrey A. Zonder, MD
    Wayne State University
    Detroit, MI

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Blazing the Trail to Better Patient Outcomes: Erythroid Maturation Agents in Beta-Thalassemia

    This program is supported by an educational grant from Bristol Myers Squibb


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    La Nouvelle Orleans Ballroom C

    For In-Person Participants Only

    This 1-hour CME-accredited Friday Satellite Symposium will focus on emerging erythroid maturation agents for the treatment of transfusion dependent (TDT) and non-transfusion dependent (NTD) ß-thalassemia. Hematologists and hemato-oncologists play a pivotal role in treating TDT and NTD ß-thalassemia. Learners will hear expert perspectives and practical guidance in improving the care of patients with ß-thalassemia, therefore increasing competence in treating ß-thalassemia in clinical practice.

    Educational Objectives:

    • Describe the clinical rationale for targeting erythroid maturation for the treatment of ß-thalassemia
    • Discuss the latest evidence for the use of novel erythroid maturation agents for the treatment of ß-thalassemia
    • Outline patient-centered strategies to optimize long-term management of patients with ß-thalassemia

    Chair:

    Ashutosh Lal, MD
    University of California San Francisco Benioff Children’s Hospital
    Oakland, CA

    Speaker:

    Sujit Sheth, MD
    Weill Cornell Medicine
    New York, NY

    Answers In CME Inc , Answers in CME Inc.
    Email: [email protected]

    Registration for In-Person Program

    Challenging Cases in Relapsed/Refractory Follicular Lymphoma

    This program is supported by Bristol Myers Squibb and Epizyme, Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire A

    In this live symposium, expert faculty will discuss how to approach challenging cases of relapsed/refractory follicular lymphoma (R/R FL) in an increasingly complicated treatment landscape. The discussion will highlight approved, and emerging therapies, and future directions, with the focus on newer therapies such as EZH2 inhibitors, immunomodulators, monoclonal antibodies, chemotherapy, and chimeric antigen receptor (CAR) T cells. The faculty will also explore how these novel and emerging agents fit into a treatment paradigm that has undergone dramatic changes in recent months. A “Case Challenge” breakout session is included that will allow the audience to engage in small-group discussions about a variety of patient management considerations. The program will conclude with a panel discussion and Q&A session with the experts, during which audience members may present challenging cases from their own practices.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    'D' is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective

    This program is supported by Sanofi Genzyme


    3:00 p.m. - 6:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom C

    For In-Person Participants Only

    This program will discuss the latest data, share perspectives and best practices, and forecast applications of critical clinical challenges and questions regarding identifying rare hematologic disorders and the importance of differential diagnosis when treating patients who present with hematologic symptoms of unknown origin. Expert faculty will challenge the audience to play the role of the detective as they approach each patient case to uncover the underlying disease at play ultimately. Audience members will be encouraged to look for 'clues' as they diagnose each patient, similar to how a detective would solve a case. After solving each case, the faculty will present a comprehensive overview of available treatment options for each rare disease. The program is designed to take an investigational approach to treat rare hematologic diseases and encourage interaction between faculty and audience.


    Chair:

    Pramod K. Mistry, MD, PhD, FRCP
    Yale University
    New Haven, CT

    Speakers:

    Nichola Cooper, MD
    Imperial College
    London, ENG, United Kingdom

    Eli Muchtar, MD
    Associate Professor of Medicine, Mayo Clinic College of Medicine and Science
    Rochester, MN

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program

    Experts Under the Microscope: Evaluating the Role of Maintenance Therapy in Long-Term Management of AML

    This program is supported by Haymarket Medical Education and Bristol Myers Squibb


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    343-345

    For In-Person Participants Only

    To bridge clinical and educational gaps surrounding the role of maintenance therapy in long-term management of AML and to improve patient care, clinicians require up-to-the-minute education on how to best implement individualized, evidence-based treatment. To achieve these goals, Haymarket Medical Education (HME) will utilize their expertise and experience from recent hematology/oncology clinician education to develop and implement a multi-format educational initiative consisting of the following components: (1) Expert Perspectives Panel Discussion - This lively expert panel discussion will include three hematologic oncologists and feature topics surrounding AML maintenance therapy including patient eligibility criteria, injectable vs oral formulations, clinical guideline recommendations, clinical efficacy and safety data, and toxicity mitigation strategies; (2) Experts Under the Microscope - This engaging intervention will put each of the three faculty members in the “hot seat” where they will be asked specific questions surrounding pressing and controversial topics AML management. “Hot seating” is an educational strategy that invites learners to recount specific events, explore motivation, and multiple perspectives related to a topic, event, or idea. Topics will include consideration of patient preferences when selecting therapy, transplant vs maintenance therapy in transplant-eligible patients, and barriers to addressing healthcare disparities.

    Chair:

    Amir T. Fathi, MD
    Massachusetts General Hospital
    Boston, MA

    Speakers:

    Maximilian F. Stahl, MD
    Harvard Medical School
    Boston, MA

    Andrew H. Wei, MBBS,PhD
    Monash University
    Melbourne, Australia

    Beth Kurdock , Haymarket Medical Education
    Email: [email protected]

    Registration for In-Person Program

    JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy

    This program is supported by Bristol Myers Squibb and Sierra Oncology, a GlaxoSmithKline company


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire B

    This 90-minute live symposium will feature 1 moderator and 2 panel members, all hematology/oncology specialists with expertise in myelofibrosis (MF). The program will begin with a didactic review of the treatment landscape, including the role of current and emerging Janus kinase (JAK) inhibitors in the MF treatment paradigm. An engaging series of patient cases and expert discussion will follow. Interspersed throughout the program will be “Do You Know JAK? Quiz Questions” to engage the audience and ensure a lively and interactive session.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Let’s Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls

    This program is supported by Global Blood Therapeutics, Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Empire CD

    This 90-minute interactive symposium will feature a panel of 3 expert faculty who will present data and have a lively, in-depth discussion on the diagnosis and treatment of patients with sickle cell disease (SCD). The activity will mimic a talk-show theme, which will allow for audience interaction utilizing various participant engagement techniques throughout the activity. In addition, a portion of the symposium will be designated to discussing real-world patient cases and integration of best clinical approaches for improving patient outcomes. Finally, a patient will share their own experiences with living with SCD.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome

    This program is supported by AbbVie, Actinium Pharmaceuticals, BioMea Fusion, Gilead Sciences, Inc., GlycoMimetics, Inc., and Rigel Pharmaceuticals, Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Hyatt Regency New Orleans
    Celestin EFGH

    This will be a 90-minute live symposium featuring 1 moderator and 3 panel members with expertise treating higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML). The symposium will follow a lively talk show style format, using various “programming segments” and faculty-provided patient cases as the basis for discussion. Key points surrounding patient management considerations in the diagnosis and treatment of HR-MDS and AML will be discussed, as well as the unmet needs and potential future directions in the treatment algorithms. Live polling questions and faculty Q&A throughout will ensure maximum audience interaction and an organic educational experience.

    Vikki R. Chavis, Medscape LLC
    Email: [email protected]

    Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings

    This program is supported by Seagen Inc., and Takeda Pharmaceuticals U.S.A., Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    208-210

    Most patients with advanced Hodgkin lymphoma (HL) achieve a complete response following first-line chemotherapy with or without CD30-targeted therapy. However, key unmet clinical needs remain, including effective pretransplant treatment options and better options for relapsed/refractory disease. Thus, there is a need for education regarding current and emerging novel therapeutic approaches in the management of HL.

    This Medical Crossfire® will bring together clinical experts in lymphoma to highlight evolving approaches to the diagnosis and treatment of patients with HL. Evidence-based assessments of current standards of practice and the most important clinical trials will set the stage for each case-based Medical Crossfire® discussion session, which will address newly diagnosed patients, relapsed/refractory disease, and pediatric patients. Additionally, strategies to maximize the safety of treatment regimens in patients with HL will be evaluated.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

    This program is supported by ImmunoGen, Inc., Menarini-Stemline, and Mustang Bio, Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    243-245

    This hybrid satellite will be the ideal mix informative didactic sections, case-based portions, and engaging multidisciplinary faculty discussion. It will provide the opportunity for participants to reflect on the disease burden and unmet needs for patients, review important safety and efficacy data for recently approved and emerging therapies for BPDCN, and strategies to integrate novel therapies into treatment plans, and compare their practices with those of experts and peers.

    This particular format will be the ideal style for clinicians the opportunity to review potential real-world clinical scenarios through case-based discussion, reflect on how they might handle particular cases, integrate relevant evidence into treatment paradigms, and compare their practices with those of experts and peers as a vehicle that enhances learning of these types of key emerging treatment concepts.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Navigating New Terrain in Chemotherapy-Induced Anemia: Hem/Onc Perspectives and Evidence-Supported Strategies for Improving Care with Intravenous Iron

    This program is supported by American Regent


    3:00 p.m. - 6:00 p.m. Central time

    Ernest N. Morial Convention Center
    393-396

    This timely educational activity is targeted to hematologists/oncologists and their interprofessional team of hematology/oncology nurses, nurse practitioners, physician assistants, and pharmacists who manage patients with cancer. After providing comprehensive context for cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states, including etiology, pathophysiology, clinical gravity, and the central role of inflammation, top hem/onc experts will guide attendees through an incisive overview of the evolving and expanding clinical trial evidentiary base for IV iron products for CRA/CIA management, emphasizing both combinatorial and monotherapeutic approaches. Recent pivotal monotherapy trials such as IRON-CLAD will be a preeminent focus. An exploration of current expert consensus guidelines from NCCN, ASCO/ASH, and ESMO will segue the session into a case-based conclusion that will allow attendees to implement all they have learned into real-world clinical scenarios.

    Chair:

    George M. Rodgers, MD, PhD
    University of Utah
    Salt Lake City, UT

    Speakers:

    Michael Auerbach, MD
    Auerbach Hematology and Oncology
    Baltimore, MD

    David H. Henry, MD
    Vice Chair, Department of Medicine
    Philadelphia, PA

    Patricia Locantore-Ford, MD
    Clinical Professor of Medicine, Hematology/Oncology
    Philadelphia, PA

    Jessica Hall , Creative Educational Concepts
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management

    This program is supported by Geron and Gilead Sciences, Inc.


    3:00 p.m. - 6:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom AB

    This CME activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported through educational grants from Geron and Gilead Sciences, Inc.

    It’s a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. As a result, the new therapeutic mandate has expanded beyond the use of conventional strategies to include the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies.

    In this PeerView MasterClass, experts will examine the connection between the latest evidence and real-world practice when utilizing principles of personalized care to integrate novel therapies into risk-adapted MDS management. Foundational lectures will link directly to "Case Forum" discussions that explore baseline prognostic assessment and focus on how novel therapeutics can help develop individualized care plans across low-, intermediate-, and high-risk disease. The future of MDS isn’t an abstraction—it’s NOW. Register now for this pivotal learning opportunity!

    Margaret Walker, Peerview Institute For Medical Education
    Email: [email protected]

  • Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)

    This program is supported by educational grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi Genzyme


    7:00 p.m. - 10:00 p.m. Central time

    Hyatt Regency New Orleans
    Celestin ABCD

    This CME-accredited program will focus on the management of patients with multiple myeloma. Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 4 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The Working Group will be video-recorded and RTP will select excerpts for presentation during the live meeting. The agenda for the symposium will be divided into 5 modules, each featuring the presentation and discussion of select video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, clinician attendees will use iPads to participate in a premeeting survey related to the topics, questions and cases that will be discussed. Polling results will be interspersed throughout each module to foster additional debate.

    Sylvia Eriksen, Research To Practice
    Email: [email protected]chtopractice.com

    Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration

    This program is supported by educational grants from BeiGene and Lilly. Provided by Clinical Care Options, LLC.


    7:00 p.m. - 10:00 p.m. Central time

    Hyatt Regency New Orleans
    Elite B

    This innovative live satellite symposium will feature a review and discussion of patient case studies and key clinical trial data with renowned clinical experts providing their perspectives on recent advances on the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) and mantle cell lymphoma (MCL). Along with the presenting faculty, attendees will be challenged to interactively manage clinically relevant cases and additionally will have multiple opportunities to directly interact with faculty in a dynamic question and answer format. Critical insights on the similarities and differences among multiple different BTK inhibitors including emerging noncovalent BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. Discussion and case topics will include: 1) Mechanisms, pharmacokinetics, pharmacodynamics, and efficacy of currently available BTK inhibitors 2) The evolving treatment paradigm in CLL/SLL and MCL including treatment-naïve and relapsed/refractory disease 3) Emerging next-generation BTK inhibitors 4) Safety considerations for BTK inhibitors in the management of CLL/SLL and MCL 5) Practical case discussions relevant to optimizing the selection of specific BTK inhibitors for individual patients.

    Chair:

    Jeff P. Sharman, MD
    US Oncology Oncology Research
    Eugene, OR

    Speakers:

    Ian W. Flinn, MD PhD
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville, TN

    Susan M. O'Brien
    UCI Cancer Center
    Orange, CA

    Patience Merullo , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?

    This program is supported by Incyte Corporation, Orca Bio, Pharmacyclics, Sanofi, and ST Shared Services, LLC, a Mallinckrodt Company


    7:00 p.m. - 10:00 p.m. Central time

    Sheraton New Orleans
    Grand Ballroom DE

    Graft-versus-host disease (GvHD) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Outcomes for patients have improved substantially due to the advent of effective prophylactic approaches, as well as novel treatment options in both the acute and chronic settings. In particular, targeted therapies directed against Janus kinase 1/2, Bruton’s tyrosine kinase, and rho-associated coiled-coil containing protein kinase offer opportunities to improve outcomes in patients for whom corticosteroids are no longer suitable.

    In this live symposium, experts will discuss evolving best practices for prediction, prevention, and management of GVHD. These concepts will be presented in Medical Crossfire format, which supplements evidence-based presentations with debates and conversations about key challenges that face the multidisciplinary team, placed in the context of challenging case discussions.

    Dayna Kleinstein, Physicians' Education Resource, LLC
    Email: [email protected]

    Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes

    This program is supported by Chiesi USA


    7:00 p.m. - 10:00 p.m. Central time

    VIRTUAL PROGRAM

    • Format: This FSS will include a mix of didactic lectures interspersed with panel discussions and plenty of time for audience Q&A.
    • Goal: Improve physician knowledge about the impact and complications associated with iron overload in vulnerable patients, and increase competence to implement appropriate treatment for iron overload based on current data and patient-specific needs

    Chair:

    Trisha E. Wong, MD, MS
    Oregon Health & Science University
    Portland, OR

    Speakers:

    Ross M. Fasano, MD
    Emory University School of Medicine
    Atlanta, GA

    Vip Viprakasit, MD, Dphil
    Mahidol University
    Bangkok, Thailand

    John C Wood, MD, PhD
    Keck School of Medicine of USC
    Los Angeles, CA

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for Virtual Program